medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Evaluation of the diagnostic value of YiDiXie™-SS in thyroid ultrasound-positive patients

Huimei Zhou[1,2,3#], Yutong Wu[1,2,4#] Xutai Li[1,2,3#], Chen Sun[1,2,3], Zhenjian Ge[1,2,4], Wenkang Chen[1,2,4], Yingqi Li[1,2,5], Shengjie Lin[1,2,4], Pengwu Zhang[1,2], Wuping Wang[1,2,5], Siwei Chen[1,2,5], Wei Li[6], Huiying Hu[7*], Yongyan Cui[8*], Jinsong He[9*], Yongqing Lai[1,2*]

1 Department of Urology, Peking University Shenzhen Hospital, Shenzhen, 518036; 2Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036; 3 The Fifth Clinical Medical College of Anhui Medical University, Hefei 230032; 4 Shantou University Medical College, Shantou, Guangdong 515041; 5 Shenzhen University Health Science Center, Shenzhen, China 518055; 6 Shenzhen KeRuiDa Health Technology Co. , Ltd. , Shenzhen, 518071; 7 Department of Ultrasound, Peking University Shenzhen Hospital, Shenzhen, 518036; 8 Department of Plastic Surgery, Peking University Shenzhen Hospital, Shenzhen, 518036; 9 Department of Breast and Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen, 518036.

# Contributed equally to this work.

*Correspondence: Yongqing Lai, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: yqlord@163.com; Jinsong He, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: hjssums@sohu.com; Yongyan Cui, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: cyy8188@163.com; Huiying Hu, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: 2423301581@qq.com.

Background: Thyroid tumor, as an endocrine tumor with increasing incidence, causes a heavy economic burden. Ultrasound scanning is widely used for screening or preliminary diagnosis of thyroid tumors, but its large number of false-positive results brings unnecessary mental pain, expensive examination costs, physical injury and other adverse consequences. There is an urgent need to find a convenient, cost-effective and noninvasive method to reduce the false-positive rate of thyroid ultrasound. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS in thyroid ultrasound-positive patients.

Patients and methods: 360 subjects (malignant group, n=342; benign group, n=18) were finally included in this study. The remaining serum samples were collected and tested by YiDiXie™ all-cancer detection kit. The sensitivity and specificity of YiDiXie™-SS were evaluated respectively.

Results: The sensitivity of YiDiXie™-SS in the malignant group was 98.5%(95% CI: 96.6% - 99.4%; 337/342) with a false negative rate of 1.5%(95% CI: 0.6% - 3.4%; 5/342). The specificity of YiDiXie™-SS for the benign group was 66.7%(95% CI: 43.7% - 83.7%; 12/18), and the false positive rate was 33.3%(95% CI: 16.3% - 56.3%; 12/18). This means that YiDiXie™-SS reduces the false positive rate by 66.7%(95% CI: 43.7% - 83.7%; 12/18) with essentially no increase in malignancy leakage.

Conclusion: YiDiXie™-SS significantly reduces the false-positive rate of thyroid ultrasound-positive patients without increasing the number of under-diagnosed malignant tumors. YiDiXie™-SS has vital diagnostic value in thyroid ultrasound-positive patients, and is expected to solve the problem of "high false-positive rate of thyroid ultrasound".

Clinical trial number: ChiCTR2200066840.

Key words: Thyroid cancer, Ultrasound Scan, False-positive, YiDiXie™-SS

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

INTRODUCTION

Thyroid cancer is the most common endocrine malignancy and the fastest growing solid cancer in terms of incidence[1]. In 2020, there were 586,000 cases of thyroid cancer globally, which ranked 9th in terms of incidence among all malignant tumors[2]. In 2022, there were more than 821,000 cases of thyroid cancer globally in terms of total incidence, thyroid cancer ranks seventh among the most common cancers[3]. In recent years, there has been a rapid increase in incidence in many countries, dominated by papillary thyroid cancer[4], which is largely attributed to the increasing use of ultrasound scanning and ultrasound-guided aspiration biopsies. Over 470,000 females and 90,000 males in the 12 countries counted may be overdiagnosed with thyroid cancer within 20 years[5]. Overdiagnosis due to ultrasound scanning leads to unnecessary fine-needle aspiration (FNA) biopsies, a dramatic increase in the diagnosis of thyroid cancer and subsequent surgery[6]. Overdiagnosis of thyroid cancer has prompted changes in clinical practice or guidelines in several countries[7-10]. As a result, thyroid tumors pose a serious threat to human health and a heavy economic burden.

Thyroid ultrasound produces not only a large number of overdiagnoses [11-13], but also a large number of false positive results. Studies have found that the risk of thyroid cancer in any patient who receives a subsequent diagnosis of nodules is only about 7-15%[14-18]. False-positive results for thyroid tumors imply misdiagnosis of benign disease as malignancy.Since puncture biopsy is usually taken in patients with positive results of ultrasound[10,19-20]. As a result, patients with false-positive thyroid ultrasound will have to bear unnecessary mental anguish, expensive tests, physical harm, and other adverse consequences. Based on the large and yearly increasing incidence of thyroid cancer[2-3], false-positive results of thyroid ultrasound are becoming an increasing healthcare burden for mankind. Therefore, there is an urgent need to find a convenient, cost-effective and noninvasive method to reduce the false-positive rate of thyroid ultrasound.

Based on the detection of miRNAs in serum, Shenzhen KeRuiDa Health Technology Co., Ltd. has developed "YiDiXie™ all-cancer test" (hereinafter referred to as the "YiDiXie™ test")[21]. With only 200 milliliters of whole blood or 100 milliliters of serum, the test can detect multiple cancer types, enabling detection of cancer at home[21]. The "YiDiXie™ test" consists of three independent tests: YiDiXie™-HS, YiDiXie™-SS and YiDiXie™-D[21].

The purpose of this study is to evaluate the diagnostic value of YiDiXie ™ -SS in thyroid ultrasound-positive patients.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

PATIENTS AND METHODS

Study design

This work is part of the sub-study "Evaluating the diagnostic value of the YiDiXie ™ test in multiple tumors" of the SZ-PILOT study (ChiCTR2200066840).

The SZ-PILOT study (ChiCTR2200066840) is a single-centre, prospective, observational study. Subjects who signed a pan-informed consent form for donation of remaining samples at the time of admission or physical examination were enrolled, and 0.5 ml of their remaining serum samples were collected for this study.

The study was blinded. Neither the laboratory personnel who performed the YiDiXie ™ test nor the KeRuiDa laboratory technicians who determined the results of the YiDiXie™ test were aware of the subjects' clinical information. The clinical experts who assessed the clinical information of the subjects were also unaware of the results of the YiDiXie™ test.

The study was approved by the Ethics Committee of Peking University Shenzhen Hospital and was conducted in accordance with the International Conference on Harmonization for "Good clinical practice guidelines" and the Declaration of Helsinki.

Participants

Patients with thyroid ultrasound findings of BI-RADS category 4 or 5 were included in this study. The two groups were enrolled separately, with all subjects who met the inclusion criteria being consecutively included.

The study initially included inpatients with "suspected (solid or haematological) malignancy" who had signed a general informed consent form for donation of the remaining samples. Subjects with a postoperative pathological diagnosis of "malignant tumor" were included in the malignant group and those benign disease were included in the benign group. Subjects with ambiguous pathological findings were excluded from the study.

Subjects who failed the serum sample quality test prior to the YiDiXie™ test were excluded from the study. For further information on enrollment and exclusion, please see our prior work[21].

Sample collection, processing

The serum samples used in this study were obtained from serum left over after a normal clinic visit, without drawing additional blood. Approximately 0.5 ml of serum samples were collected from the remaining serum of subjects in the Medical Laboratory Department and stored at -80°C for subsequent use in the YiDiXie™ test.

YiDiXie™ test

The YiDiXie ™ test is performed using the YiDiXie ™ all-cancer detection kit, an in vitro diagnostic kit developed and manufactured by Shenzhen KeRuiDa Health Technology Co., Ltd. It is an in vitro diagnostic kit for use in fluorescent quantitative PCR. It determines the presence of cancer in a subject's body by measuring the expression levels of dozens of miRNA biomarkers in the serum. It predefines appropriate thresholds for each miRNA biomarker to ensure that each miRNA marker is highly specific, and integrates these independent assays in a concurrent testing format to significantly increase the sensitivity and maintain the specificity for broad-spectrum cancers.

The YiDiXie™ test consists of three distinctly different tests: YiDiXie™-Highly Sensitive (YiDiXie™-HS), YiDiXie ™-Super Sensitive(YiDiXie ™-SS) and YiDiXie™-Diagnosis (YiDiXie™-D). YiDiXie™-HS has been developed with sensitivity and specificity in mind. YiDiXie ™ -SS significantly increased the number of miRNA tests to achieve extremely high

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

sensitivity for all clinical stages of all malignancy types. YiDiXie ™ -D dramatically increases the diagnostic threshold of individual miRNA tests to achieve very high specificity (very low false diagnosis rate) for all malignancy types.

Perform the YiDiXie ™ test according to the instructions of the YiDiXie ™ test all-cancer detection kit. Refer to our prior work[21] for detailed procedure.

The raw test results are analyzed by the laboratory technicians of Shenzhen KeRuiDa Health Technology Co., Ltd. and the results of the YiDiXie™ test are determined to be "positive" or "negative".

Clinical data collection

For this study, clinical, pathological, laboratory, and imaging data were extracted from the subjects' hospitalized medical records or physical examination reports. All clinical staging was assessed by trained clinicians according to the AJCC staging manual (7th or 8th edition)[22-23].

Statistical analyses

For demographic and baseline characteristics, descriptive statistics were reported. For categorical variables, the number and percentage of subjects in each category were calculated; For continuous variables, the total number of subjects (n), mean, standard deviation (SD) or standard error (SE), median, first quartile (Q1), third quartile (Q3), minimum, and maximum values were calculated. 95% confidence intervals (CIs) for multiple indicators were calculated using the Wilson (score) method.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

RESULTS

Participant disposition

360 study participants were involved in this research (n = 342 cases for the malignant group and 18 cases for the benign group). The 360 participants' clinical and demographic details are listed in Table 1.

In terms of clinical and demographic traits, the two study subject groups were similar (Table 1). The mean (standard deviation) age was 40.7 (10.86) years and 72.8% (262/360) were female.

Table 1. Participants' demographic and clinical manifestation

	Malignant (n =342)		Benign (n =18)		Total (N = 360)	
Age, years						
Mean (SD)	40.5	(10.66)	46.1	(13.32)	40.7	(10.86)
Median (Q1,Q3)	39	(32, 47)	52	(33, 58)	39	(32, 48)
Min, max	21,	73	22,	69	21,	73
Sex, n (%)						
Female	247	(72.2)	15	(83.3)	262	(72.8)
Male	95	(27.8)	3	(16.7)	98	(27.2)
Body mass index (kg/m2)						
n	339		18		357	
Mean (SD)	23.2	(3.24)	22.3	(2.84)	23.1	(3.22)
Median (Q1,Q3)	22.9	(20.7, 25.1)	21.9	(20.4, 23.8)	22.9	(20.7, 25.0)
Min, max	14.6	35.7	16.1	27.4	14.6	35.7
Body mass index category, n (%)						
Underweight	14	(4.1)	1	(5.6)	15	(4.2)
Benign	197	(57.6)	13	(72.2)	210	(58.3)
Overweight	101	(29.5)	4	(22.2)	105	(29.2)
Obese	27	(7.9)	0	(0)	27	(7.5)
Missing	3	(0.9)	0	(0)	3	(8.0)
AJCC clinical stage						
Stage I	342	(100)			342	(100)

Q1,Q3, first quartile, third quartile; SD, standard deviation.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Diagnostic Performance of YiDiXie™-SS

As shown in Table 2, the sensitivity of YiDiXie™-SS for the malignant group was 98.5%(95% CI: 96.6% - 99.4%; 337/342), with a false negative rate of 1.5%(95% CI: 0.6% - 3.4%; 5/342).

The specificity of YiDiXie™-SS for the benign group was 66.7%(95% CI: 43.7% - 83.7%; 12/18), with a false positive rate of 33.3%(95% CI: 16.3% - 56.3%; 12/18).

This means that YiDiXie™-SS reduces the false positive rate by 66.7%(95% CI: 43.7% - 83.7%; 12/18) with essentially no increase in malignancy leakage.

Table 2. The performance of YiDiXie™-SS test

	Malignant	Benign	Total
	342	18	360
Test positive	337	6	345
Test negative	5	12	15

SEN = 337/342 = 98.5% (96.6% - 99.4%)
FNR = 5/342 = 1.5% (0.6% - 3.4%)
SPE = 12/18 = 66.7% (43.7% - 83.7%)
FPR = 6/18 = 33.3% (16.3% - 56.3%)

Two-sided 95% Wilson confidence intervals were calculated.
SEN, Sensitivity. SPE, Specificity. FNR, False negative rate. FPR, False positive rate.



Figure 1. Basic flowchart of the "YiDiXie™ test".

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

DISCUSSION

Reasons for choosing YiDiXie™-SS

The YiDiXie™ test consists of 3 tests with very different characteristics: YiDiXie™-HS, YiDiXie™-SS and YiDiXie ™ -D. Among them, YiDiXie ™ -HS combines high sensitivity and high specificity. YiDiXie ™ -SS has very high sensitivity for all malignant tumour types, but slightly lower specificity. YiDiXie™-D has very high specificity for all malignant tumour types, but lower sensitivity.

In patients with positive ultrasound scans for thyroid tumors, both sensitivity and specificity of further diagnostic methods are important. On the one hand, sensitivity is important. Lower sensitivity means a higher rate of false negatives. When the result of this diagnostic method is negative, the diagnosis usually ends for that patient. A higher false-negative rate means that more malignancies are missed, which will lead to delays in their treatment, progression of the malignancy, and possibly even development of advanced stages. Patients will thus have to bear the adverse consequences of poor prognosis, poor quality of life, and high cost of treatment.

On the other hand, specificity is important. Lower specificity means a higher rate of false positives. Thyroid tumors are usually resected or puncture biopsied when the result of this diagnostic method is positive. Higher false positive rate means that more cases of benign tumors are subjected to surgical resection or puncture biopsy. This undoubtedly substantially increases patients' mental suffering, expensive surgery or examination costs, physical injuries, and other adverse consequences.

Therefore, the trade-off between sensitivity and specificity is essentially a trade-off between "fewer malignant tumors missed" and "fewer benign tumors misdiagnosed". In general, when a benign tumor is misdiagnosed as a malignant tumor, it is usually treated with simple tumor excision or puncture biopsy rather than radical resection. Thus, false positives for thyroid tumors do not lead to serious consequences in terms of organ loss. Thus, for thyroid tumors, it is far more important to have "fewer malignant tumors missed" than "fewer benign tumors misdiagnosed". Therefore, YiDiXie™-SS, with its very high sensitivity but slightly lower specificity, was chosen to reduce the false positive rate of ultrasound scans for thyroid tumors, rather than the highly sensitive and specific YiDiXie™-HS or YiDiXie™-D, which has very high specificity (very low false positive rate) but low sensitivity.

Clinical Implications of YiDiXie™-SS in thyroid ultrasound-positive patients

As shown in Table 2, the sensitivity of YiDiXie™ -SS in the malignant group was 98.5%(95% CI: 96.6% - 99.4%; 337/342), and the false negative rate was 1.5%(95% CI: 0.6% - 3.4%; 5/342). The specificity of YiDiXie ™ -SS for the benign tumor group was 66.7%(95% CI: 43.7% - 83.7%; 12/18), with a false positive rate of 33.3%(95% CI: 16.3% - 56.3%; 12/18) (Table 2). These results indicate that, while maintaining sensitivity close to 100%, YiDiXie™-SS reduces the false-positive rate of 66.7%(95% CI: 43.7% - 83.7%; 12/18) in thyroid ultrasound-positive patients.

As mentioned earlier, a missed diagnosis of thyroid cancer means a delay in treatment, while a false-positive thyroid ultrasound means an unnecessary puncture biopsy. These results imply that YiDiXie™-SS drastically reduces the probability of erroneous puncture biopsy of benign thyroid tumors with virtually no increase in malignant leakage diagnosis.

In other words, without basically increasing the delayed treatment of malignant tumors, YiDiXie™ -SS substantially reduces the mental suffering, expensive examination or surgery costs, physical injuries, and other adverse consequences for patients with false-positive thyroid ultrasound. Hence, YiDiXie ™ -SS well fulfills the clinical demands and has important clinical significance and wide application prospects.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

YiDiXie ™ -SS is expected to solve the problem of "high false-positive rate of thyroid ultrasound"

Firstly, YiDiXie ™ -SS has excellent diagnostic performance in patients with positive thyroid tumor ultrasound scans. As mentioned, YiDiXie ™ -SS significantly reduces the probability of wrong surgery or wrong puncture biopsy for benign thyroid tumors with essentially no increase in malignant tumor underdiagnosis.

Secondly, YiDiXie ™ -SS reduces physician burdens and allows for rapid treatment of malignancies that might otherwise be postponed. When the ultrasound scan is positive, the patient usually undergoes puncture biopsy. The timely completion of these puncture biopsies is directly dependent on the number of physician. In many parts of the world, appointments of several months or even more than a year are available for thyroid puncture biopsy. It is inevitable that the treatment of malignant cases would be delayed. It is not uncommon for thyroid ultrasound-positive patients awaiting treatment to develop malignant progression or even distant metastases.

As shown in Table 2, "YiDiXie™-SS reduces the false-positive rate of 66.7%(95% CI: 43.7% - 83.7%; 12/18) in patients with positive thyroid tumor ultrasound scans with essentially no increase in malignant tumor underdiagnosis. As a result, YiDiXie ™ -SS significantly relieves surgeons of unnecessary workload and facilitates the timely treatment of malignant tumors that would otherwise be delayed.

Finally, the YiDiXie™-SS enables "just-in-time" diagnosis of patients with positive ultrasound scans for thyroid tumors. On the one hand, the YiDiXie™ test requires only a tiny amount of blood and allows patients to complete the diagnostic process non-invasively without having to leave their homes. Only 20 μL of serum are required to complete a YiDiXie™ test, which is equivalent to approximately one drop of whole blood (one drop of whole blood is approximately 50 μL, which yields 20-25 μL of serum). Taking into account the pre-test sample quality assessment test and 2-3 repetitions, 0.2 ml of whole blood is sufficient for the YiDiXie™ test. The 0.2 ml of finger blood can be collected at home by the average patient using a finger blood collection needle without the need for venous blood collection by medical personnel, allowing the patient to complete the diagnostic process non-invasively without having to leave the patient's home.

On the other hand, the diagnostic capacity of YiDiXie™-SS is nearly unlimited. Figure 1 shows the basic flow chart of YiDiXie™ test, from which it can be seen that YiDiXie™-SS's diagnostic capacity is virtually unlimited. YiDiXie™-SS not only does not require a doctor or medical equipment, but also does not require medical personnel to collect blood.

As a result, YiDiXie ™ -SS is completely independent of the number of clinician and medical facilities, and has a virtually unlimited testing capacity. As a result, YiDiXie™-SS enables "just-in-time" diagnosis of patients with a positive ultrasound scan for thyroid tumors, without the need for patients to wait anxiously for an appointment.

In short, YiDiXie™-SS can play an important role in patients with positive thyroid tumor ultrasound scans, and is expected to solve the world's problem of "high false-positive rate of thyroid ultrasound scans".

Limitations of the study

Firstly, the number of cases in this study was small and future clinical studies with larger sample sizes are needed for further assessment.

Secondly, this study was a malignant tumor-benign tumor control study in inpatients, and future cohort studies of patients with positive thyroid tumor ultrasound scans are needed for further assessment.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Finally, this study was a single-centre study, which may have led to some degree of bias in the results of this study. Future multi-centre studies are needed to further assess this.

CONCLUSION

YiDiXie ™ -SS significantly reduces the false-positive rate of thyroid ultrasound-positive patients without increasing the number of under-diagnosed malignant tumors. YiDiXie ™ -SS has vital diagnostic value in thyroid ultrasound-positive patients, and is expected to solve the problem of "high false-positive rate of thyroid ultrasound".

FUNDING

This study was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).

REFERENCES

1. Global Burden of Disease Cancer C, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E et al.: Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 4: 1553-1568, 2018.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71: 209-249, 2021.
3. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74: 229-263, 2024.
4. Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S and Dal Maso L: Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9: 225-234, 2021.
5. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L: Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med 2016, 375(7):614-617.
6. Ullmann TM, Papaleontiou M and Sosa JA: Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis. J Clin Endocrinol Metab. 108: 271-280, 2023.
7. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K et al.: Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2: 1023-1029, 2016.
8. Panato C, Vaccarella S, Dal Maso L, Basu P, Franceschi S, Serraino D, Wang K, Lei F, Chen Q, Huang B et al.: Thyroid Cancer Incidence in India Between 2006 and 2014 and Impact of Overdiagnosis. J Clin Endocrinol Metab. 105: 2507-2514, 2020.
9. Patel KN: Noninvasive Encapsulated Follicular Variant of Papillary Thyroid "Cancer" (or Not): Time for a Name Change. JAMA Oncol. 2: 1005-1006, 2016.
10. Togawa K, Ahn HS, Auvinen A, Bauer AJ, Brito JP, Davies L, Kesminiene A, Laurier D, Ostroumova E, Pacini F et al.: Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC. Lancet Oncol. 19: 1280-1283, 2018.
11. Li M, Dal Maso L and Vaccarella S: Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 8: 468-470, 2020.
12. Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA and Wenig BM: Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309931; this version posted July 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Clin Pathol. 130: 736-744, 2008.

13. Franc B, de la Salmoniere P, Lange F, Hoang C, Louvel A, de Roquancourt A, Vilde F, Hejblum G, Chevret S and Chastang C: Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol. 34: 1092-1100, 2003.
14. Angell TE, Maurer R, Wang Z, Kim MI, Alexander CA, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM et al.: A Cohort Analysis of Clinical and Ultrasound Variables Predicting Cancer Risk in 20,001 Consecutive Thyroid Nodules. J Clin Endocrinol Metab. 104: 5665-5672, 2019.
15. Wang CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, Zeiger MA, Westra WH, Wang Y, Khanafshar E et al.: A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 21: 243-251, 2011.
16. Guth S, Theune U, Aberle J, Galach A and Bamberger CM: Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 39: 699-706, 2009.
17. Barroeta JE, Wang H, Shiina N, Gupta PK, Livolsi VA, Baloch ZW: Is fine-needle aspiration (FNA) of multiple thyroid nodules justified? Endocrine pathology 2006, 17(1):61-65.
18. Leenhardt L, Grosclaude P, Chérié-Challine L: Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid : official journal of the American Thyroid Association 2004, 14(12):1056-1060.
19. Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H et al.: Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 20: 925-951, 2022.
20. Gordon AJ, Dublin JC, Patel E, Papazian M, Chow MS, Persky MJ, Jacobson AS, Patel KN, Suh I, Morris LGT et al.: American Thyroid Association Guidelines and National Trends in Management of Papillary Thyroid Carcinoma. JAMA Otolaryngol Head Neck Surg. 148: 1156-1163, 2022.
21. Chen Sun, Chong Lu, Yongjian Zhang, et al. Evaluation of the Multi-Cancer Early Detection (MCED) value of YiDiXie™-HS and YiDiXie™-SS [J]. medRxiv, 2024: doi: 10.1101/2024.03.11.24303683.
22. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 67: 93-99, 2017.
23. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17: 1471-1474, 2010.